Imaging Biomarkers for Cancer Clinical Trials

Our shared service offers standardized MRI imaging protocols for
single-site and multi-site cancer clinical studies. We also offer advanced
image processing to extract quantitative biomarker information from
radiological images. 

For more information, please contact Dr. Natarajan Raghunand .

DCE-MRI in a Phase I Study of an Anti-Angiogenic Agent. 
A significant decrease in Ktrans was observed in the spleen at the end of a 24 h drug infusion, indicating anti-VEGF activity.

 

Image2.jpg

   

DCE-MRI in a Phase I Study of an Anti-Vascular Agent. 
A significant decrease in Ktrans was observed in the tumor at the end of a 4 h drug infusion. In this study, DCE-MRI showed promise as a pharmacodynamic marker of drug activity.
 
 
DCE-MRI in a Phase I Study.jpg